SCHEMBL5652637

SCHEMBL5652637

COCCNC(C)(C)c1ccc(N)c(C2=C(C)C(C)CCC2)n1

nearest known ligand 0.31

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.31
KCNH2 Q12809 1/20 0.31
HRH2 P25021 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5652636 0.85 SYK (0.36)
SCHEMBL3096004 0.79 HRH3 (0.34) HRH3HRH2
SCHEMBL5653253 0.71 CSF1R (0.42)
SCHEMBL5653251 0.61 CSF1R (0.45)
SCHEMBL15418068 0.58 GAA (0.43) HRH3
SCHEMBL15418083 0.55 CSF1R (0.53)
SCHEMBL30069318 0.53 HRH2 (0.42) HRH3HRH2
SCHEMBL3251857 0.53 CYP1A2 (0.47)
SCHEMBL28850738 0.51 ALDH1A1 (0.37)
SCHEMBL517222 0.51

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9452996-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-09-27 US disclosed
EP-2021329-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-04-13 EP disclosed
US-20160046602-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-02-18 US disclosed
US-9221797-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2015-12-29 US disclosed
US-20140148448-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-05-29 US disclosed
US-8674100-B2 Inhibitors of C-FMS kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2014-03-18 US disclosed
EP-2687516-A1 Inhibitors of C-FMS Kinase Janssen Pharmaceutica N.V. (BE) 2014-01-22 EP disclosed
US-20070249649-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249649-A1 INHIBITORS OF C-FMS KINASE FES, MUSK, FRK HRH3 685/4885KCNH2 880/4885HRH2 549/4885
US-20140148448-A1 INHIBITORS OF C-FMS KINASE FES, MUSK, FRK HRH3 685/4885KCNH2 880/4885HRH2 549/4885
US-20160046602-A1 INHIBITORS OF C-FMS KINASE FES, MUSK, FRK HRH3 685/4885KCNH2 880/4885HRH2 549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.